Rated Fund 2013-19. Invests in a diverse range of healthcare companies
This trust has twice been highly commended in the Best Large Trust category in Money Observer’s annual trust awards, no mean feat when it was up against more than 100 trusts from a variety of sectors. It invests in a diversified portfolio of worldwide pharmaceutical, biotechnology and healthcare equipment, technology and services companies.
Sven Borho, a founder partner of US-based specialist healthcare fund manager OrbiMed Capital, has run the trust since its inception in 1995. He was joined by co-manager Trevor Polischuk in 2017. They are supported by a team of 80 investment professionals who carry out extensive research to find potential investments.
The managers seek innovation and growth in the global healthcare industry and invest in healthcare companies that offer the greatest return potential. Risk is spread through global exposure and diversification across different healthcare sub-sectors.
At the end of 2018, pharmaceutical and biotech companies each accounted for 30% of the portfolio, which consisted of 90 holdings. The majority of the top 10 holdings were large, profitable companies, collectively accounting for 40% of assets. More than 75% was invested in US stocks, but there was also 10% in emerging markets, 9% in Europe and 6% in Asia.
Skerritts Wealth Management is a long-term supporter of the trust and points to its record as the best performer across the whole investment trust sector since 1995. Healthcare is a key theme in its portfolios given the defensive nature of the sector and the world’s ageing population.
The board operates an active discount management policy so shares in the trust typically trade around the value of underlying assets.
Narrative and ratings content all as of 01 January 2019.See all Money Observer rated funds
|Takeda Pharmaceutical Co Ltd||8.84 %|
|Boston Scientific Corp||6.43 %|
|Merck & Co Inc||5.55 %|
|Alexion Pharmaceuticals Inc||4.03 %|
|Novartis AG||3.52 %|
|Edwards Lifesciences Corp||3.42 %|
|Neurocrine Biosciences Inc||3.21 %|
|Novo Nordisk A/S B||3.02 %|
|Vertex Pharmaceuticals Inc||2.97 %|
|Abbott Laboratories||2.97 %|
|United States||68.67 %|
|Europe - ex Euro||8.53 %|
|Asia - Emerging||6.82 %|
Polischuk joined OrbiMed in 2003 as an analyst covering the major global pharmaceutical industry. Previously, he worked at Lehman Brothers as a senior research analyst covering the U.S. pharmaceutical industry.
Sven H. Borho, CFA, is a founding General Partner of OrbiMed. Mr. Borho is a portfolio manager for OrbiMed’s public equity funds and he heads the firm’s trading efforts. He started his career in 1991 when he joined Mehta and Isaly as a Senior Analyst covering European pharmaceutical firms and biotechnology companies worldwide. In 1993, Mr. Borho became portfolio manager to investment funds under management. Mr. Borho studied business administration at Bayreuth University in Germany and received a M. Sc. (Econ.) from The London School of Economics; he is a citizen of both Germany and Sweden.
Data provided by Morningstar.
The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.
This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.
You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.